Solta Medical's novel addition to its aesthetic device solutions, the Clear + Brilliant pélo™ laser, offers personalized results with groundbreaking laser hair removal [LHR] technology to make it fast and simple with minimal pain for anyone to get rid of unwanted hair.
The Clear + Brilliant pélo™ laser provides a highly effective treatment in a short amount of time due to its innovative linear scanning technology and the largest treatment window in the market. A full back takes only 8-12 minutes, and full legs take about 36 minutes. After 5-6 treatments, patients can see the results they want, and still have money in their pocket for the long run.
Each treatment can be customized depending on the individual's needs, and patient comfort is enhanced by minimizing pain on contact through a sapphire glass handpiece that quickly chills to 0°C. So patients and physicians can rest easy that their individual needs are met.
To view the multimedia release go to:
http://www.multivu.com/players/English/7621831-clear-brilliant-pelo-laser-hair-removal/
Ways to Conserve Energy without breaking your budget.
https://powersaver1200.net/ways-to-co...
Simple yet effective, every little action you do adds up to a lot! You can conserve energy quickly and easily.
By implementing just a few energy saving solutions, you can really make a dent in your power consumption and electricity bills.
Saving Energy will not only help you and your family, but it will protect all of mankind and mother Earth.
With our energy saving devices, we have solutions to help you save easily and effectively! By focusing on the motors/appliances in your home, you can quickly laser target the biggest energy consumers in your home and make them as energy efficient as possible- WITHOUT spending thousands of dollars!
Energy Conservation doesn't have to be difficult. By using just a few of my free electricity tips on my site, you can EASILY save 10%. Start conserving electricity in your home or business today and stop suffering from high power bills and stress! http://youtu.be/9g7ZtSev1a8
Nintex, the leader in workflow automation, today announced the upcoming release of Nintex Hawkeye, a new cloud-based workflow analytics service. For the thousands of global companies that have collectively deployed more than a million Nintex workflows, they can now capture, monitor, measure, and assess workflow analytics that provide actionable intelligence to understand and improve their business processes.
Nintex Hawkeye automatically captures people and process data and then generates reports and dashboards with analytics to help business and IT decision makers understand important, yet often unanswerable, questions like: which processes are automated, what functions do they perform, when and how often do processes run, who’s involved in the process, what content is accessed, how effective are the processes and how might the processes be improved?
To view the multimedia release go to:
http://www.multivu.com/players/English/7589551-nintex-hawkeye-cloud-analytics/
https://youtu.be/eRFhYose0vQ Business owners all over the internet are waiting. They know the importance of providing live chat support to their customers, but until now, finding a simple customer support system with easy-to-use live chat capabilities was like finding a needle in a haystack. Well the needle has been found! The wait is over! Rhino Support offers a personalized support system for business owners who are looking for an effective support system that can grow with their needs.
Solar photovoltaic (PV) systems can generate clean, cost-effective power anywhere the sun shines. This video shows how a PV panel converts the energy of the sun into renewable electricity to power homes and businesses.
Source: U.S. Department of Energy
Cision, a leading global media intelligence and communications solution provider and portfolio company of GTCR, announced that Kevin Akeroyd has been named global chief executive officer (CEO), effective today. Akeroyd succeeds Peter Granat, who established the company’s position as a global public relations and marketing cloud leader, and will transition to chairman of the Cision Board of Directors.
Akeroyd has more than 25 years of experience in reshaping modern digital, social and mobile marketing globally. Most recently he was general manager and senior vice president at Oracle Marketing Cloud where he orchestrated and executed the industry’s most prolific acquisition strategy, including Marketing Automation, Omni-Channel Campaign Management, Web Personalization, Content Marketing, DMP, Mobile Marketing, Data, and X-Device Orchestration. Under Akeroyd’s leadership, Oracle went from a non-entity to the #2 player in the entire industry in under three years, growing the business in 29 countries globally, and boasting the highest organic growth rate of all the major Marketing Cloud providers rate three years running. Integrating the solutions and the go-to-market, Akeroyd and Oracle created the Enterprise Marketing Platform category and have led it from the onset.
To view the multimedia release go to:
http://www.multivu.com/players/English/7896951-cision-kevin-akeroyd-new-global-ceo/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
With the February launch of GOPO® Rosehip with Galactolipids, a natural, plant-based joint care supplement clinically proven to support joint health, the natural supplement is gaining traction and helping millions who suffer joint pain due to age, sports injuries, etc. Used extensively in Europe, GOPO is now available in the U.S. and proven effective in supporting long-term joint mobility and cartilage care.
GOPO Rosehip with Galactolipids is made from 100% specially-cultivated, natural rosehip using a patented extraction process and is the only product of its kind to contain a high level of galactolipids - a key component of the rosehip which may play a valuable role in the care of joints and joint tissues.
To view the multimedia release go to:
http://www.multivu.com/players/English/7918251-new-gopo-joint-care-all-natural-supplement/
Today, Cision announced the launch of its new integrated platform, the Cision Communication Cloud™. The new offering is the first of its kind in the communications industry to bring the power of the cloud to earned media and incorporates many of Cision’s award-winning technologies into one integrated platform, providing an effective way to connect, scale and accurately measure the impact of earned media communications.
“Communications teams have had to manage very disparate systems, content, data, and analytics. When it comes to the mission critical communications function, the power of the cloud has yet to be unleashed,” said Cision CEO Kevin Akeroyd. “Just as the marketing mega players of Silicon Valley have successfully built cloud platforms to transform sales, marketing and other functions, Cision is now bringing the power of the cloud to earned media.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7931751-cision-communication-cloud/
Today, Cision announced the launch of its integrated platform, the Cision Communication Cloud™.
This new offering is the first of its kind in the UK and European communications industry to bring the power of the cloud to earned media and incorporates many of Cision’s award-winning technologies, including Gorkana and PR Newswire products and services, into a single integrated platform, providing an effective way to connect, scale and accurately measure the impact of earned media communications.
Jeremy Thompson, CEO (EMEA & India), Cision/PR Newswire, said: “At Cision, we appreciate that PRs and communicators are busier than ever before, as the power and importance of reputation grows. We have set out to help our users assert control by integrating the essential communications data sets and tools they need at their fingertips in one place.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7961251-cision-communication-cloud/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
